Outlook Therapeutics Stages a Comeback Just in Time for a July Showdown
20.06.2026 - 16:38:20 | boerse-global.de
Outlook Therapeutics has clawed its way back from the brink, with shares surging nearly 30% over the past seven trading sessions to close at $1.58. The rally buys crucial breathing room as the company faces two make-or-break deadlines in July that will determine both its Nasdaq listing and its access to the US market.
The immediate threat is the Nasdaq's minimum bid price requirement of $1.00 per share. With the current level, Outlook now enjoys a 58% buffer — a far cry from the precarious position it occupied just weeks ago. The stock has now closed above $1 for six consecutive trading days, helped in large part by a 35.3% spike on June 17 that turned the tide.
FDA Priority Review Resets the Clock
The surge was triggered by the FDA's decision to formally accept the resubmitted Biologics License Application for ONS-5010, the company's ophthalmic formulation of bevacizumab marketed as LYTENAVA for wet age-related macular degeneration. The agency classified the submission as a Class-1 resubmission and set a PDUFA date of July 29, 2026.
The path to this point has been anything but smooth. Outlook previously received three Complete Response Letters — one in 2023 and two in 2025 — before finally securing a formal dispute resolution in May 2026, in which the FDA acknowledged the drug's efficacy. That win paved the way for the current accelerated review.
Should investors sell immediately? Or is it worth buying Outlook Therapeutics?
A Second July Hurdle
Even as investors focus on the FDA verdict, another critical event falls on July 16. On that date, shareholders face a potential dilution risk — likely tied to a reverse split or capital increase vote — that could alter the stock's trajectory. The company must navigate that vote while maintaining its Nasdaq compliance through the end of the month.
European Footing Strengthens
Across the Atlantic, LYTENAVA is already making headway. The product received marketing authorization in the European Union and the United Kingdom in 2024, and is now actively commercialized in Germany, Austria, and the UK. That foundation has produced what the company calls a "solid initial revenue base."
In Switzerland, Outlook has signed a distribution agreement with Mediconsult AG, with a market launch penciled in for 2027.
Outlook Therapeutics at a turning point? This analysis reveals what investors need to know now.
All Eyes on July 29
The FDA's decision on July 29 will be the final piece of the puzzle. If approved, LYTENAVA would become the first authorized bevacizumab formulation for wet AMD in the United States. But until then, the stock's ability to stay above $1 remains the company's first line of defense. On a year-to-date basis, the shares are still marginally in the red — down about 0.7% — underscoring how much hangs on the coming weeks.
Ad
Outlook Therapeutics Stock: New Analysis - 20 June
Fresh Outlook Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
